William Blair Reaffirms Buy Rating for Portola Pharmaceuticals (PTLA)
PTLA has been the topic of a number of other research reports. Citigroup reiterated a buy rating and set a $74.00 price objective on shares of Portola Pharmaceuticals in a research report on Thursday, December 28th. Oppenheimer set a $80.00 price objective on Portola Pharmaceuticals and gave the stock a buy rating in a research report on Tuesday, December 19th. Goldman Sachs Group began coverage on Portola Pharmaceuticals in a research report on Friday, December 1st. They set a buy rating and a $75.00 price objective on the stock. Morgan Stanley reiterated an overweight rating and set a $81.00 price objective (up previously from $75.00) on shares of Portola Pharmaceuticals in a research report on Friday, October 6th. Finally, BidaskClub upgraded Portola Pharmaceuticals from a strong sell rating to a sell rating in a research report on Thursday, December 21st. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $70.65.
Shares of Portola Pharmaceuticals (PTLA) traded down $0.57 during trading hours on Monday, hitting $48.84. The stock had a trading volume of 638,245 shares, compared to its average volume of 1,409,400. The company has a debt-to-equity ratio of 0.24, a current ratio of 8.31 and a quick ratio of 8.31. The firm has a market capitalization of $3,190.00, a price-to-earnings ratio of -11.31 and a beta of 1.21. Portola Pharmaceuticals has a 12-month low of $22.71 and a 12-month high of $67.10.
Portola Pharmaceuticals (NASDAQ:PTLA) last announced its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($1.41) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.49) by $0.08. Portola Pharmaceuticals had a negative return on equity of 110.46% and a negative net margin of 938.19%. The firm had revenue of $3.83 million for the quarter, compared to the consensus estimate of $4.71 million. During the same quarter last year, the business posted ($1.64) earnings per share. The firm’s revenue was down 58.9% compared to the same quarter last year. analysts forecast that Portola Pharmaceuticals will post -4.94 earnings per share for the current year.
In other Portola Pharmaceuticals news, Director Henry Ward Wolff sold 12,000 shares of Portola Pharmaceuticals stock in a transaction on Friday, December 15th. The stock was sold at an average price of $47.00, for a total value of $564,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. 5.50% of the stock is owned by insiders.
Large investors have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Portola Pharmaceuticals by 14.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,078 shares of the biopharmaceutical company’s stock valued at $117,000 after purchasing an additional 258 shares during the period. Jacobi Capital Management LLC purchased a new stake in Portola Pharmaceuticals in the second quarter valued at $125,000. QS Investors LLC purchased a new stake in Portola Pharmaceuticals in the second quarter valued at $147,000. Oppenheimer Asset Management Inc. raised its position in Portola Pharmaceuticals by 251.2% in the third quarter. Oppenheimer Asset Management Inc. now owns 2,862 shares of the biopharmaceutical company’s stock valued at $155,000 after purchasing an additional 2,047 shares during the period. Finally, Canada Pension Plan Investment Board purchased a new stake in Portola Pharmaceuticals in the third quarter valued at $178,000. Institutional investors own 87.25% of the company’s stock.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.